ALDX
Aldeyra Therapeutics, Inc.
Nasdaq · usd
Stock performance
How Aldeyra Therapeutics, Inc. (ALDX) stock has performed from one day to one year, with its 52-week range.
- 1D
- +4.01%
- 1W
- +5.28%
- 1M
- -4.36%
- YTD
- -87.07%
- 1Y
- -86.36%
- 52-wk range
- $0.53 – $5.93
Key statistics
Today's trading snapshot for ALDX: day range, open, previous close, volume and market cap.
- Day range
- —
- Open
- —
- Prev close
- $0.67
- Volume
- 0
- Market cap
- $40.41M
- Shares out
- 60.36M
Valuation and profitability ratios: P/E, P/S, ROE
Valuation and profitability ratios for Aldeyra Therapeutics, Inc.: P/E, P/S, P/B, ROE and more.
- P/E
- —
- P/S
- —
- P/B
- 1.10
- P/FCF
- —
- ROE
- -54.3%
- ROA
- -44.1%
- Debt/Equity
- 0.00
- Div yield
- 0.00%
As of Nov 13, 2026
8-K filings
Material corporate events Aldeyra Therapeutics, Inc. has disclosed to the SEC on Form 8-K.
- Regulatory decisionNov 9, 2026
In June 2023, we received a Complete Response Letter for our New Drug Application ("NDA") for ADX-2191 for the treatment of primary vitreoretinal lymphoma ("PVRL"), which stated that there was a lack of substantial evidence of effectiveness due to a lack of adequate and well-controlled investigations.
- Investor presentationSep 29, 2026
Aldeyra is holding a conference call regarding the announcement on September 29, 2026. A copy of the supplemental presentation, which will be referenced during the conference call and will be posted on Aldeyra's website is furnished herewith as Exhibit 99.1 and is incorporated by reference herein.
- Lease agreementJul 30, 2026
On July 28, 2026, Aldeyra Therapeutics, Inc. executed a lease agreement (the "Office Lease") with Bradford Street, L.L.C. for approximately 4,067 square feet of office space located at 23 Bradford Street, Concord, Massachusetts. The Office Lease commences on September 1, 2026 and the term with respect to the Premises shall be for a period ending on September 30, 2029. The Company intends to use the Premises as its corporate headquarters. The Office Lease provides for a monthly base rent of $12,201.00, increasing each year as indicated in the Office Lease.
- Regulatory decisionJul 15, 2026
On July 14, 2026, Aldeyra Therapeutics, Inc. (Aldeyra) received minutes (the Minutes) from a Type A meeting, held on June 10, 2026 with the U.S. Food and Drug Administration (FDA), regarding potential resubmission of the New Drug Application (NDA) of reproxalap for the treatment of dry eye disease.
- Annual meeting resultsJun 10, 2026
At the 2026 Annual Meeting held on June 9, 2026, the following proposals were submitted to the stockholders of the Company... The Company's stockholders elected the following director to serve as a Class III director until the 2029 annual meeting of stockholders... The Company's stockholders ratified the appointment of BDO USA, P.C. as the Company's independent registered public accounting firm for the fiscal year ending December 31, 2026... The Company's stockholders approved, on a non-binding, advisory basis, the compensation of the Company's named executive officers.
ALDX short interest
How heavily ALDX is shorted: shares short, days to cover and average daily volume.
- Days to cover
- 3.4
- Short interest
- 3.16M
- Avg volume
- 917.9K
As of · reported to FINRA twice monthly.
ALDX news
The latest news and headlines about Aldeyra Therapeutics, Inc. (ALDX).
- RARE's Fayuvi Approval Spurs Second PRV Sale Worth $203M in a WeekpositiveZacks Investment Research· Oct 15, 2026
- Here's Why You Should Add ANRO Stock to Your Portfolio NowpositiveZacks Investment Research· Oct 14, 2026
- Syndax Stock Falls 16% as Phase II Fibrosis Study Misses Primary GoalnegativeZacks Investment Research· Oct 14, 2026
- Prime Medicine Stock Rallies Nearly 26% in a Month: Here's WhypositiveZacks Investment Research· Oct 12, 2026
- PMVP Stock Rises 19% in 3 Months: Here's What You Need to KnowpositiveZacks Investment Research· Oct 12, 2026
Frequently asked questions
What is the Aldeyra Therapeutics, Inc. (ALDX) stock price today?
Massive provides real-time and historical Aldeyra Therapeutics, Inc. (ALDX) quotes via REST API, WebSocket and MCP.
What is Aldeyra Therapeutics, Inc.?
Aldeyra Therapeutics Inc is a biotechnology company engaged in developing and commercializing next-generation medicines to improve the lives of patients with immune-mediated and metabolic diseases.
What is the short interest in ALDX?
As of Oct 30, 2026, ALDX has 3.16M shares short and 3.4 days to cover.
What exchange is ALDX listed on?
Aldeyra Therapeutics, Inc. (ALDX) trades on Nasdaq in USD, in the PHARMACEUTICAL PREPARATIONS industry.
Build with AI
Build an analysis of ALDX with your agent
Point Claude or ChatGPT at the Massive MCP server and recreate this page from live data.
Connect the Massive MCP server (API reference: massive.com/docs/llms.txt) and build a ALDX analysis: the latest quote, key ratios (P/E, P/S, ROE), short interest, recent insider activity and the latest news.
Nothing on this page is investment advice. All data and content is provided for informational purposes under our Terms of Service.